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Abstract
Background: Recent studies demonstrated an impact of the nervous system on particle-induced osteolysis, the
major cause of aseptic loosening of joint replacements.
Methods: In this study of MG-63 osteoblast-like cells we analyzed the influence of ultra-high molecular weight
polyethylene (UHMWPE) particles and the neurotransmitter alpha-calcitonin gene-related peptide (CGRP) on the
osteoprotegerin/receptor activator of nuclear factor-B ligand/receptor activator of nuclear factorB (OPG/RANKL/
RANK) system. MG-63 cells were stimulated by different UHMWPE particle concentrations (1:100, 1:500) and
different doses of alpha-CGRP (10-7 M, 10-9 M, 10-11 M). RANKL and OPG mRNA expression and protein levels were
measured by RT-PCR and Western blot.
Results: Increasing particle concentrations caused an up-regulation of RANKL after 72 hours. Alpha-CGRP showed a
dose-independent depressive effect on particle-induced expression of RANKL mRNA in both cell-particle ratios.
RANKL gene transcripts were significantly (P < 0.05) decreased by alpha-CGRP treatment after 48 and 72 hours.
OPG mRNA was significantly down-regulated in a cell-particle ratio of 1:500 after 72 hours. Alpha-CGRP
concentrations of 10-7 M lead to an up-regulation of OPG protein.
Conclusion: In conclusion, a possible osteoprotective influence of the neurotransmitter alpha-CGRP on particle
stimulated osteoblast-like cells could be shown. Alpha-CGRP might be important for bone metabolism under
conditions of particle-induced osteolysis.
Background
Mechanical wear in the joint of a total hip replacement is
responsible for a severe inflammatory reaction due to the
release of cytokines and other soluble mediators that
favor osteoclast generation, bone resorption and, in turn,
prosthetic loosening [1]. The discovery of calcitonin
gene-related peptide (CGRP) -immunoreactive nerve
fibres in the interface membrane and elevated CGRP
levels in synovial fluids of loosened arthoplasty suggested
a linkage between the nervous system and aseptic loosen-
ing [2,3].
In our previous in-vivo study of alpha-CGRP deficient
mice we demonstrated an influence of the neurotransmit-
ter alpha-CGRP and the importance of the osteoprote-
gerin/receptor activator of nuclear factor-B ligand/
receptor activator of nuclear factorB (OPG/RANKL/
RANK) system on particle-induced osteolysis [4]. The
neurotransmitter alpha-CGRP has multiple physiological
roles. For example, it affects the metabolism of skeletal
muscle, the liver and the kidneys, and inhibits glycogen
synthesis [5,6]. It acts as a potent vasodilatator, as a neuro-
trophic effector and as a mediator in the neurogenic
inflammatory response [7,8]. Alpha-CGRP receptors are
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expressed in brain tissue, adrenal and pituitary glands, the
exocrine pancreas, peripheral tissue and on osteoblasts
[9-11]. The OPG/RANKL/RANK system plays a key role
in the cross-talk between osteoblasts and osteoclasts
[12,13]. RANKL and OPG are members of a ligand-recep-
tor system that directly regulates osteoclast differentiation
and bone resorption, and both are produced and secreted
by osteoblastic lineage cells [13,14]. On the one hand,
RANKL binds to RANK, which is expressed on osteoclast
progenitors, and leads to osteoclast activation. On the
other hand, OPG binds to RANKL and thereby inhibits
osteoclast activation. The osteoblast function can be
described by alkaline phosphatase specific activity [15].
To closer study our in-vivo results, we analyzed MG-




Alpha-CGRP (Sigma Aldrich, Cat. No. C0167, Saint
Louis, Missouri, USA) was dissolved in 1% acetic acid or
water and stored at -20°Celsius before use. During cell
seeding, alpha-CGRP was added daily to the experimen-
tal wells to form different concentrations (10-7 M,
10-9 M or 10-11 M), as introduced by Villa et al. while
an alpha-CGRP-free medium was added to the control
group [16].
Preparation of wear particles
The commercially pure ultra-high molecular weight poly-
ethylene (UHMWPE) particles (Ceridust VP 3610, Clar-
iant, Gersthofen, Germany) with a mean particle size
(given as equivalent circle diameter) of 1.74 ± 1.43 μm
(range 0.05-11.06) were used in this study [17]. For endo-
toxin removal, the particles were treated for 24 hours
with 99% ethanol at room temperature and were after-
wards dried in a desiccator. The efficacy of the method
was checked using Limulus Amebocyte Lysate (LAL)
Assay (Charles River, Kent, United Kingdom) with a sen-
sitivity of 0.25 EU/ml according to the manufacturer’s
directions. The test was found to be negative. Subse-
quently, particles were re-suspended in 10% endotoxin-
free fetal calf serum (FCS), vortexed and treated in a
sonicating water bath. Flow cytometry was used to mea-
sure the number of particles per unit volume of solution.
MG-63 cells
The human osteoblast-like MG-63 cell line (CRL-1427™,
ATCC) was obtained from the American Type Culture
Collection. The cell line was cultured in RPMI 1640 med-
ium (PAA, Pasching, Austria), supplemented with 100 U
of penicillin G/ml (Gibco, BRL, Eggenstein, Germany),
100 μg of streptomycin/ml (Gibco), 2 mM L-glutamine
(Gibco) and 10% fetal calf serum (PCS) at 37°C in a
humidified atmosphere (5% CO2 and 95% air).
For the experiment, MG-63 cells were seeded into 6-well
flat bottomed culture plates at the quantity of approxi-
mately 1.5 × 105 cells per well. After 24 hours, an 80%
confluence of the cells was reached. The supernatant was
removed and a fresh medium containing UHMWPE parti-
cles was added. During this procedure, different quantities
of particles were added to form two different cell-particle
ratios (1:100 and 1:500).
Isolation of RNA and quantitative Real Time RT-PCR
analysis
Total RNA was isolated using Qiashraddle (Qiagen,
Hilden, Germany) and purified using the RNeasy Mini
Kit (Qiagen, Hilden, Germany). Both procedures were
performed according to the manufacturer’s specification.
The purification included a DNase treatment using the
RNase free DNase Set (Qiagen, Hilden, Germany). The
yield and purity of the RNA was measured photometri-
cally. RNA was analyzed by quantitative real time poly-
merase chain reaction (RT-PCR) in a Rotorgene Cycler
(Corbett Research, Mortlake, Australia) using the
QuantiFast SYBR Green RT-PCR kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions.
A conventional PCR was performed to obtain a product
of amplification suitable for the construction of standard
curves with the real-time PCR procedures. The incor-
poration of Sybr Green into the PCR products was mon-
itored in real time after each PCR cycle, resulting in the
calculation of the threshold cycle or Ct value that
defines the PCR cycle number at which an exponential
growth of PCR products begins. PCR cycle conditions
were as follows: 10 minutes at 50°C, 5 minutes at 95°C,
35 to 40 cycles of 10 seconds at 95°C and 30 seconds at
60°C. Each PCR procedure included a negative control
reaction without a template. To exclude residual DNA
contamination of the RNA samples, RT-PCR was also
performed without reverse transcriptase. For mRNA
amplification, the validated primers were obtained from
Qiagen (Qiagen, Hilden, Germany): b-actin (Cat. No.
QT00095431), RANKL (Cat. No. QT00215614) and
OPG (Cat. No. QT00014294). The PCR products were
sequenced and found to be identical to the published
sequences. The b-actin housekeeping gene was used as
reference for the relative quantification of the gene of
interest, which was expressed as the ratio of ‘concentra-
tion of the target’ to ‘concentration of b-actin’.
Western Blot
MG-63 cells were stimulated with and without particles
(the cell-particle ratios were 1:100 and 1:500 respec-
tively) for 24, 48, 72 hours. The cells were washed with
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ice-cold phosphate-buffered saline (PBS) twice and
directly lysed in Laemmli buffer. The lysate was soni-
cated, boiled for 5 minutes and centrifuged at 16,000 g
for 10 minutes at 4°C. The supernatant was recovered
as total cell lysate, sub-packaged and stored at -80°C.
Equal amounts of protein (10 μg) were separated by 8%
SDS-PAGE and electro-transferred to 0.45 μm polyviny-
lidene difluoride membranes (Millipore, Bedford, USA).
Following transfer, membranes were blocked with a
solution of 0.1% Tween 20/TBS (TBS/T) containing 5%
non-fat milk for one hour at room temperature and
then incubated with monoclonal mouse anti-human
OPG antibody (GTX11994, GeneTex, USA, final dilu-
tion 1:300) or rabbit polyclonal human RANKL
(AB1862, Chemicon, Temecula, California, USA, final
dilution 1:3500) overnight at 4°C. Specifically bound pri-
mary antibodies were detected with peroxidase-coupled
secondary antibody and enhanced chemiluminescence
(Cell Signaling Technologies, Beverly, MA). The bands
were visualized by nitroblue tetrazolium/5-bromo-4-
chloro-3-indolyl-phosphate. Glyceraldehyde-3-Phosphate
Dehydrogenase (GAPDH) was used as house keeping
gene.
For densitometric analyzes, blots were scanned and
quantified using Quantity One analysis software (Bio-
Rad, Hercules, CA, USA). The results were expressed as
the percentage of GAPDH immunoreactivity.
Alkaline phosphatase specific activity
Upon termination of culture, the medium was carefully
aspirated from each well. The QuantiChromeTM Alka-
line Phosphatase Assay Kit (Cat. No. DALP-250; BioAs-
say Systems, Hayward, CA) was used to measure alkaline
phosphatase (AP) activity levels in lysate samples of 104
cells, following the manufacturer’s instructions.
Statistical analysis
Results from representative experiments are shown.
They were expressed as mean ± standard deviation. A
repeated measurement ANOVA for all continuous
dependent variables determined if there was (a) a time-
by-group interaction effect, (b) a time effect and (c)
inter-group effect. When F-values corresponding to a
time-by-group interaction effect for a given variable
were found to be significant, simple effects testing was
performed to determine a time effect within each
experimental group. Subsequently, one-way ANOVA
tests were used to determine the detectable change
between the groups at each time point. One-way
ANOVA tests, at each time point relative to the pre-
vious time point, determined if there were significant
changes from each time-point. A p-value < 0.05 was
considered to indicate statistical significance.
Results
RANKL mRNA expression of MG-63 cells was signifi-
cantly elevated in high particle concentrations after
48 hours and in both particle concentrations after
72 hours (Figure 1A).
In the cell-particle ratio of 1:100 RANKL mRNA expres-
sion was significantly decreased by all concentrations of
alpha-CGRP at all time-points (P < 0.05) (Figure 1B). A
significant effect of time on RANKL mRNA expression
inhibited by different concentrations of alpha-CGRP was
found.
In particle concentrations of 1:500 RANKL mRNA
expression was significantly decreased by all concentra-
tions of alpha-CGRP after 48 and 72 hours (P < 0.05)
(Figure 1C). The effect of time on RANKL mRNA
expression in cell particle ratio of 1:500 inhibited by dif-
ferent concentrations of alpha-CGRP was not significant
(p = 0.09). No significant differences of inhibition
between the tested alpha-CGRP concentrations in both
particle concentrations were revealed.
The time course of OPG mRNA expression in MG-63
cells differed after treatment with cell-particle concentra-
tions of 1:100 and 1:500 (Figure 1D). In cell-particle con-
centrations of 1:100 OPG mRNA-expression significantly
increased after 72 hours (P < 0.05). In cell-particle con-
centrations of 1:500 a significant increase of OPG mRNA
was found after 24 hours turning to a significant decrease
after 72 hours.
Alpha-CGRP stimulation in cell-particle concentra-
tions of 1:100 lead to an up-regulation of OPG mRNA.
These results were significant in high (10-7 M) alpha-
CGRP concentrations after 24 and 48 hours (P < 0.05)
(Figure 1E). In cell particle concentrations of 1:500 a
significant up-regulation of OPG mRNA was found after
treatment with high (10-7 M) alpha-CGRP concentra-
tions after 72 hours (Figure 1F).
The detected RANKL protein levels detected by Wes-
tern blot analysis showed a significant increase in both
particle groups after 48 and 72 hours (Figure 2). Alpha-
CGRP treatment lead to a significant decrease of
RANKL protein after 48 and 72 hours. The analyzed
alpha-CGRP concentrations did not show significantly
differences.
Western blot analysis in a cell-particle ratio of 1:100
showed significantly elevated OPG protein levels after
24 and 48 hours in high alpha-CGRP concentrations.
(Figure 3B). In the cell-particle ratio of 1:500 a signifi-
cantly elevated OPG protein was found after 72 hours
(Figure 3C). The significant changes of RANKL and
OPG mRNA corresponded to the detected protein levels
(compare Figure 1, 2, 3).
To further show a possible dose-dependent influence
of alpha-CGRP we analyzed the OPG/RANKL mRNA
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ratio. In cell-particle concentrations of 1:100 after
24 hours, a significantly higher (P < 0.05) OPG/RANKL
mRNA ratio was found after treatment with high
(10-7M) alpha-CGRP concentrations compared to low
(10-11M) alpha-CGRP concentrations. The OPG/RANKL
mRNA ratio was not found to be different in cell/parti-
cle ratios of 1:500. After 48 and 72 hours the OPG/
RANKL mRNA ratio was not different between the
tested alpha-CGRP concentrations.
AP activity was significantly (P < 0.05) decreased in
cell-particle ratios of 1:100 compared to the control
group at all time points (Table 1). Cell-particle ratios of
1:500 lead to a significantly (P < 0.05) decreased AP
activity compared to the 1:100 group and the control at
all time points. All alpha-CGRP concentrations did not
change AP activity significantly at the analyzed time
points.
Discussion
Until now the effects of alpha-CGRP in polyethylene parti-
cle-induced osteolysis have not been described in detail.
This is the first time the effect of alpha-CGRP on RANKL
and OPG mRNA expression has been examined in vitro
under particle incubation. Our finding gives further sup-
port to previous reports of a linkage between neurotrans-
mitters and particle-induced osteolysis [2,4,18].
This study shows a possible interaction of osteoblasts
via the OPG/RANKL/RANK system after UHMWPE
particle and alpha-CGRP. A dysbalanced interaction
between osteoclasts and osteoblasts via the OPG/
RANKL/RANK system might be one reason for dose-
dependent particle-induced osteolysis. Our results show
a significant RANKL up-regulation by particles and a sig-
nificant dose-dependent down-regulation of RANKL pro-
duction by alpha-CGRP. The OPG results did not show
an inverse proportion of the RANKL levels as we
believed. The detected OPG levels in the cell-particle
ratio of 1:500 correspond to the literature whereas the
elevation of OPG in the cell-particle ratio of 1:100 after
72 hours does not. The up-regulation of OPG was found
after alpha-CGRP treatment in all doses at 24, 48 and 72
hours, but they did not reach significance in most groups.
Analog to the literature, high RANKL levels and low
OPG levels can cause a stimulation of osteoclasts [12,19].
The differing OPG results might be of small relevance for
the in-vivo interaction as our results show a stronger
influence of particles and alpha-CGRP on RANKL than
on OPG. The results of our study correspond to the find-
ings that macrophage-osteoclast differentiation occurs in
the presence of soluble RANKL and that this process is
inhibited by OPG [20]. We suggest that the discrepancy
between RANKL and OPG mRNA expression of osteo-
blasts affected by UHMWPE particles is one of the
reasons for periprosthetic osteolysis. The dual alpha-
CGRP-influenced enhancers of bone formation showing
down-regulated RANKL and an up-regulated OPG could
theoretically inhibit the differentiation and activity of
osteoclasts.
Figure 1 RANKL and OPG mRNA levels in MG-63 cells after particle and alpha-CGRP treatment. Time course of (A) RANKL and (D) OPG
mRNA expression of MG-63 cells after stimulation with different UHMWPE particle concentrations. Time course of UHMWPE particle-induced
RANKL mRNA expression after treatment with different alpha-CGRP doses in (B) a cell-particle ratio of 1:100 and (C) a cell-particle ratio of 1:500.
Time course of UHMWPE particle-induced OPG mRNA expression after treatment with different alpha-CGRP doses in (E) a cell-particle ratio of
1:100 and (F) a cell-particle ration of 1:500. Significant differences are marked. ((a) P < 0.05).
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In the past decade, opinions regarding the influence of
the neurotransmitter alpha-CGRP on bone metabolism
have been controversial. On the one hand, alpha-CGRP
has been shown to be a physiological activator of bone
formation [21]. Cornish et al. found that osteoblasts
respond to alpha-CGRP by increased growth [22].
Transgenic mice with an over-expression of alpha-
CGRP present a phenotype of increased trabecular bone
volume caused by an increased bone formation rate due
to osteoblast activity [23]. Alpha-CGRP knock-out mice
show a phenotype of decreased bone formation and
osteopenia [24]. Moreover, alpha-CGRP inhibits the dif-
ferentiation and recruitment of osteoclast precursors
[25,26]. On the other hand, increased trabecular bone
volume and reduced osteopenia were found in mice
lacking both alpha-CGRP and calcitonin [27]. In this
study, the effects of alpha-CGRP on the analyzed OPG/
RANKL/RANK system might activate bone formation
analog to the cell culture experiment of Cornish et al.
and the transgenic mice of Ballica et al. and Schinke
et al. [22-24,28]. We analyzed the AP specific activity to
further show an established marker of osteoblast func-
tion as described by Dean et al. [15]. The decreasing AP
activity shows the particle-dose dependent reduction of
activity of MG-63 osteoblast-like cells. The non-signifi-
cant AP activity reaction to different alpha-CGRP levels
might be due to the analyzed time course. Chen et al.
found the maximal AP activity after 25 days in MG-63
Figure 2 RANKL protein levels in MG-63 cells after particle and alpha-CGRP treatment. Time courses of RANKL protein levels in MG-63
osteoblast-like cells stimulated by UHMWPE particles and alpha-CGRP using Western blot analysis. (A) Representative Western blot for RANKL in
untreated group and the alpha-CGRP-incubated groups. Densitometric quantification of RANKL in (B) a cell-particle ratio of 1:100 and (C) a cell-
particle ratio of 1:500 with and without alpha-CGRP-incubation. RANKL protein levels are expressed relatively to GAPDH. Data are reported as
mean ± standard deviation (n = 5). ((a) P < 0.05).
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cells [29]. Further studies should focus on the time
course of AP and further osteoblast specific markers to
better understand the reaction of osteoblasts on alpha-
CGRP.
A complex of other factors besides the analyzed OPG/
RANK/RANKL system is involved in bone formation,
activation and survival of osteoblasts and osteoclasts.
Several pathways regulating the function of bone remo-
deling have been reported in the past, including TNF-
alpha/TNFR/TRAF1 and IL-6/CD126/JAK/STAT
[30,31]. Osteoblast activity is strongly regulated by sur-
rounding pH and growth factors released from resorbed
Figure 3 OPG protein levels in MG-63 cells after particle and alpha-CGRP treatment. Time courses of OPG protein levels in MG-63
osteoblast-like cells stimulated by UHMWPE particles and alpha-CGRP using Western blot analysis. (A) Representative Western blot for OPG in
untreated group and the alpha-CGRP-incubated groups. Densitometric quantification of OPG in (B) a cell-particle ratio of 1:100 and (C) a cell-
particle ratio of 1:500 with and without alpha-CGRP-incubation. OPG protein levels are expressed relatively to GAPDH. Data are reported as
mean ± standard deviation (n = 5). ((a) P < 0.05).













24 h 0.84 ± 0.02 0.82 ± 0.01 0.82 ± 0.03 0.82 ± 0.03 0.75 ± 0.04 0.73 ± 0.02 0.72 ± 0.04 0.73 ± 0.03
48 h 0.82 ± 0.04 0.81 ± 0.04 0.82 ± 0.02 0.80 ± 0.04 0.71 ± 0.02 0.71 ± 0.05 0.71 ± 0.03 0.71 ± 0.04
72 h 0.81 ± 0.03 0.80 ± 0.02 0.79 ± 0.03 0.79 ± 0.04 0.69 ± 0.03 0.70 ± 0.04 0.70 ± 0.04 0.68 ± 0.03
Alkaline phosphatase specific activity of MG-63 cells incubated with different cell-particle ratios (1:100, 1:500) and different doses of alpha-CGRP (10-7 M, 10-9 M,
10-11 M). Treatment/control ratios (T/C) are shown. Data are reported as mean ± standard deviation.
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bone matrix that stimulate osteoblasts to promote or
inhibit bone formation [32,33]. This may have an impact
on the bone mass outcome at each remodeling cycle
[34]. Furthermore, wear debris has a direct influence on
macrophage-osteoclast differentiation. Human macro-
phages isolated directly from periprosthetic tissues sur-
rounding loosened implants can differentiate into
multinucleated cells and show all the functional and
cytochemical characteristics of osteoclasts [35]. There-
fore, it can be suggested that alpha-CGRP, by activating
bone remodeling, may contribute to the precise adjust-
ment of this process favoring the gain or loss of bone
mass depending on the local environment. Finally, a dis-
crepancy between bone formation and resorption due to
alpha-CGRP might appear with the increase in the con-
centration of wear particles.
It remains uncertain whether our in vitro findings in
osteoblast-like cells can be directly transferred to an up-
regulation or down-regulation of bone formation in asep-
tic loosening of joint replacements. A limiting factor of
this study is the partial focus on MG-63 osteoblast-like
cells. These commercially available MG-63 osteosarcoma
cells are often used as model for the osteoblastic pheno-
type because of their rapid growth and their homogeneity
in the cell circle [36-40], but the OPG/RANKL/RANK
system in vivo interacts between both osteoblasts and
osteoclasts. The interaction of osteoclasts and osteoblasts
might have a major impact on the later osteoprotective
or catabolic result. Furthermore, this cell culture experi-
ments has a limited perspective of time as we analyzed
the MG-63 cells for only 72 hours. As aseptic loosening
is a process which can take years, the reactions by osteo-
blasts might change in the course of time.
Conclusion
In conclusion, the present study provides data describing
the activation of signaling pathways in an osteoblast-like
human cell under incubation with UHMWPE particles.
Our data shows significant changes of RANKL, OPG, and
AP activity due to UHMWPE particles and alpha CGRP
supporting the concept of a linkage between the peripheral
nervous system and aseptic loosening. Our results improve
the understanding of alpha-CGRP having an osteoprotec-
tive influence on particle-induced osteolysis via the OPG/
RANKL/RANK-system. Further studies of the interaction
of osteoclasts, osteoblasts, neurotransmitters, and the
OPG/RANKL/RANK system have to be undertaken to
gain a better understanding of the multifactorial process
of aseptic loosening and possible therapeutic options.
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